CoSign Electronic Signatures delivered with DataLabs Site Manager 2.0
CoSign electronic signature reduces the time and cost of clinical trials, helping sponsors and CROs comply with the FDA's 21 CFR Part 11 and GxP regulations.
PHILADELPHIA-June 19, 2006-Algorithmic Research (ARX), a leading worldwide provider of electronic signatures and data security solutions, announced from the Drug Information Association (DIA) 42nd Annual Conference an agreement to integrate its CoSign electronic signature solution with DataLabs' Site Manager 2.0 collaboration software.
This integrated solution enables sponsors and CROS to electronically sign documents, forms and agreements using standard electronic signatures, which reduces the time and cost to clinical trials while complying with the FDA's 21 CFR Part 11 and GxP regulations.
DataLabs will be at booth #1829 at the DIA Annual Conference
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
